dalazatide
Peptideexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2013 (NCT02446340)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Voltage-gated potassium channel subunit Kv1.3Supplementation
KCNA3 supplementation
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297738 ↗
Also known as
- dalazatide
- dalazatide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02435342 | Phase 1 | Oct 1, 2014 | Kineta Inc. |
| NCT02446340 | Phase 1 | Nov 1, 2013 | Kineta Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kineta Inc. | For profit | 2 | 2 | 1 | 2013 |
1 organizations
Page 1 / 1